COI and the Current Environment
Variations in Journal Disclosure and Enforcement Policies
- Califf R
DeAngelis CD, Fontanarosa PB. Conflicts over conflicts of interest [published online ahead of print March 20, 2009] [editorial]. JAMA doi:10.1001/jama.2009.480.
Armstrong D. Medical journal eases rule silencing filers of complaints. July 7, 2009. The Wall Street Journal.com http://online.wsj.com/article/SB124700923018308521.html. Accessed July 13, 2009.
Armstrong D. Medical journal eases rule silencing filers of complaints. July 7, 2009. The Wall Street Journal.com http://online.wsj.com/article/SB124700923018308521.html. Accessed July 13, 2009.
Selective Disclosures: Differences Based on Source of Funding
Wright M. Controversy surrounds witness in Vioxx trial. The Facts.com Web site. July 31, 2005. http://thefacts.com/story.lasso?ewcd=c2feba40a6deb92e. Accessed July 8, 2009.
Serious COIs Not Related to the Pharmaceutical Industry
The speech that maimed Schering and Merck. Forbes.com Web site, April 3, 2008. http://www.forbes.com/2008/04/03/vytorin-merck-schering-biz-healthcare-cx_mh_0402schering.html. Accessed July 8, 2009.
Authorship, Ghost Authorship, and Medical Writing
Medical Journals' Policies for Publishing Industry-Sponsored Research
Legal Discovery and Peer-Reviewed Publication
Concluding Comments: Industry, Publications, and Public Trust
- European Federation of Pharmaceutical Industries and Associations (EFPIA)
- International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)
- Japanese Pharmaceutical Manufacturers Association (JPMA)
- Pharmaceutical Research and Manufacturers of America (PhRMA)
- Califf R
- Goozner M
REFERENCES
- How perceived physician leadership behavior affects physician satisfaction.Mayo Clin Proc. 2008; 83: 983-988
- The contemporary medical community: leadership, mentorship, and career choices [editorial].Mayo Clin Proc. 2008; 83: 974-977
- Academic advancement of women in medicine: do socialized gender differences have a role in mentoring?.Mayo Clin Proc. 2008; 83: 204-207
- Physicians' preferences and attitudes about end-of-life care in patients with an implantable cardioverter-defibrillator.Mayo Clin Proc. 2008; 83: 1139-1141
- Advance directives: know what you want, get what you need [editorial].Mayo Clin Proc. 2007; 82: 1460-1462
- Physician participation in capital punishment.Mayo Clin Proc. 2007; 82: 1073-1082
- Should physicians participate in capital punishment?.Mayo Clin Proc. 2007; 82: 1047-1048
- Physician involvement in capital punishment: simplifying a complex calculus.Mayo Clin Proc. 2007; 82: 1043-1046
- Managing conflict of interest in clinical practice.Mayo Clin Proc. 2007; 82: 607-614
- Divergent views on managing clinical conflicts of interest [letter].Mayo Clin Proc. 2007; 82: 1013-1014
- Divergent views on managing clinical conflicts of interest [letter].Mayo Clin Proc. 2007; 82: 1013-1014
- Divergent views on managing clinical conflicts of interest [letter reply].Mayo Clin Proc. 2007; 82: 1014-1015
- Publication of market-driven research in medical journals [letter].Mayo Clin Proc. 2006; 81: 850
- Publication of market-driven research in medical journals [letter reply].Mayo Clin Proc. 2006; 81: 850-851
- Editor's note: industry support of articles published in Mayo Clinic Proceedings.Mayo Clin Proc. 2006; 81: 851-852
- Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation.JAMA. 2008; 299: 1800-1812
- Impugning the integrity of medical science: the adverse effects of industry influence [editorial].JAMA. 2008; 299: 1833-1835
- Nothing to see here: based on one company's past poor publishing practices, a top-tier medical journal misguidedly stigmatizes any paper from industry [editorial].Nat Biotechnol. 2008; 26: 476
- Guest authorship, mortality reporting, and integrity in rofecoxib studies [letter].JAMA. 2008; 300: 900-901
- Guest authorship, mortality reporting, and integrity in rofecoxib studies [letter].JAMA. 2008; 300: 901
- Guest authorship, mortality reporting, and integrity in rofecoxib studies [letter].JAMA. 2008; 300: 901
- Guest authorship, mortality reporting, and integrity in rofecoxib studies [letter].JAMA. 2008; 300: 901-902
- Guest authorship, mortality reporting, and integrity in rofecoxib studies [letter].JAMA. 2008; 300: 903-904
- Guest authorship, mortality reporting, and integrity in rofecoxib studies [letter reply].JAMA. 2008; 300: 904-905
- Guest authorship, mortality reporting, and integrity in rofecoxib studies [letter reply].JAMA. 2008; 300: 905-906
- Uniform requirements for manuscripts submitted to biomedical journals: writing and editing for biomedical publication: updated October 2008. ICMJE Web site.(Accessed July 8, 2009.)
- Trial lawyers are now focusing on lawsuits against drug makers.New York Times. May 18, 2003; (Accessed July 8, 2009.)
- Understanding financial conflicts of interest.N Engl J Med. 1993; 329: 573-576
- Trust us to make a difference: ensuring public confidence in the integrity of clinical research.Acad Med. 2001; 76: 209-214
- Reporting financial conflicts of interest and relationships between investigators and research sponsors [editorial].JAMA. 2001; 286: 89-91
- Conflict of interest in medical research, education, and practice.in: Institute of Medicine of the National Academies Web site. National Academies Press, Washington, DC2009 (Accessed July 8, 2009.)
- Conflicts of interest in clinical research: opprobrium or obsession?.Lancet. 1997; 349: 1112-1113
- Conflict of interest and the BMJ: time to take it seriously [editorial].BMJ. 1994; 308: 4-5
- The 9th annual RQ: reputations of the 60 most visible companies: a survey of the US general public. HarrisInteractive Web site.(Accessed July 8, 2009.)
- Bioequivalence of generic and brand-name levothyroxine products in treatment of hypothyroidism.JAMA. 1997; 277: 1205-1213
- Thyroid storm [editorial].JAMA. 1997; 277: 1238-1243
- Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 × 106/L CD4 cell counts: a randomized controlled trial.JAMA. 2000; 284: 2193-2202
- Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial.JAMA. 2000; 284: 1247-1255
- Reporting of 6-month vs 12-month data in a clinical trial of celecoxib [letter].JAMA. 2001; 286: 2398
- Sponsorship, authorship, and accountability [editorial].Ann Intern Med. 2001; 135: 463-466
- Depressing research [editorial].Lancet. 2004; 363: 1335
- Spitzer charges Glaxo concealed Paxil data.The Wall Street Journal. June 3, 2004; (Accessed July 8, 2009.): B1
- Clinical trial registration: a statement from the International Committee of Medical Journal Editors [editorial].Lancet. 2004; 364: 911-912
- Expression of concern: Bombardier et al. “Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.” N Engl J Med. 2000;343:1520-8 [editorial].N Engl J Med. 2005; 353 (Epub 2005 Dec 8.): 2813-2814
- Response to expression of concern regarding VIGOR study [letter].N Engl J Med. 2006; 354 (Epub 2006 Feb 22.): 1196-1199
- Response to expression of concern regarding VIGOR study [letter].N Engl J Med. 2006; 354 (Epub 2006 Feb 22.): 1198-1199
- How the New England Journal missed warning signs on Vioxx: medical weekly waited years to report flaws in article that praised pain drug: Merck seen as “punching bag.”.The Wall Street Journal (East Ed). 2006; (A10.): A1
- Food and Drug Administration Amendments Act of 2007, P.L. 110-85.(Accessed July 8, 2009.)
- Trial registration and results disclosure: impact of US legislation on sponsors, investigators, and medical journal editors.Curr Med Res Opin. 2008; 24 (Epub 2008 May 6.): 1683-1689
- Scope and impact of financial conflicts of interest in biomedical research: a systematic review.JAMA. 2003; 289: 454-465
- Pharmaceutical industry sponsorship and research outcome and quality: systematic review.BMJ. 2003; 326: 1167-1170
- Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ.BMJ. 2002; 325: 249
- Publication bias: a brief review for clinicians.Mayo Clin Proc. 2000; 75: 1284-1288
- Factors associated with failure to publish large randomized trials presented at an oncology meeting.JAMA. 2003; 290: 495-501
- Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research.CMAJ. 2004; 171: 735-740
- Randomized clinical trials: what gets published, and when?.CMAJ. 2004; 170: 481-483
- Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles.JAMA. 2004; 291: 2457-2465
- Reporting conflicts of interest, financial aspects of research, and role of sponsors in funded studies [editorial].JAMA. 2005; 294: 110-111
- Conflicts of interest and independent data analysis in industry-funded studies [letter].JAMA. 2005; 294: 2575
- Conflicts of interest and independent data analysis in industry-funded studies [letter].JAMA. 2005; 294: 2575-2576
- Conflicts of interest and independent data analysis in industry-funded studies [letter reply].JAMA. 2005; 294: 2576-2577
- Extra scrutiny for industry funded trials: JAMA's demand for an additional hurdle is unfair—and absurd.BMJ. 2005; 331: 1350-1351
- The influence of money on medical science [editorial].JAMA. 2006; 296 (Epub 2006 Aug 7.): 996-998
- A common standard for conflict of interest disclosure. Center for Science in the Public Interest Web site.(Accessed July 8, 2009.)
- The changing academic landscape. Presented at: 4th Annual Meeting of the International Society for Medical Publication Professionals; Philadelphia, PA.http://www.ismpp.org/pdf/4th%20Annual%20Meeting%20Highlights%20Newsletter%20FINAL.PDF(Accessed July 8, 2009.)Date: April 28-30, 2008
- Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment.JAMA. 2006; 295: 499-507
- Antidepressant treatment and relapse of depression during pregnancy [letter reply].JAMA. 2006; 296: 166-167
- Financial ties to industry cloud major depression study: at issue: whether it's safe for pregnant women to stay on medication: JAMA asks authors to explain.The Wall Street Journal (East Ed). July 11, 2006; (A9) (Acccessed July 8, 2009.): A1
- JAMA to tighten rules on author disclosure.The Wall Street Journal. July 12, 2006; (Accessed April 18, 2009.)
- Clinical trials of therapy versus medication: even in a tie, medication wins [letter].(BMJ Mar 5 2009. Accessed July 8, 2009.)
- The Wall Street Journal Health Blog. JAMA editor calls critic a “nobody and a nothing.”.http://blogs.wsj.com/health/2009/03/13/jama-editor-calls-critic-a-nobody-and-a-nothing/(Accessed July 8, 2009.)Date: March 13, 2009
- Medical journal decries public airing of conflicts.The Wall Street Journal. March 22, 2009; (Accessed July 8, 2009.)
- Nonprofit hits JAMA editors, urges inquiry.The Wall Street Journal. March 27, 2009; (Accessed July 8, 2009.)
- Medical group seeks probe of its journal.The Wall Street Journal. March 28, 2009; (Accessed July 8, 2009.)
- Re: Clinical trials of therapy versus medication: even in a tie, medication wins [letter reply].(BMJ. April 15, 2009. Accessed July 8, 2009.)
DeAngelis CD, Fontanarosa PB. Conflicts over conflicts of interest [published online ahead of print March 20, 2009] [editorial]. JAMA doi:10.1001/jama.2009.480.
- Resolving unreported conflicts of interest [editorial].JAMA. 2009; 302: 198-199
Armstrong D. Medical journal eases rule silencing filers of complaints. July 7, 2009. The Wall Street Journal.com http://online.wsj.com/article/SB124700923018308521.html. Accessed July 13, 2009.
- Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation.JAMA. 2008; 299: 1813-1817
- Instructions for Authors. JAMA Web site.(Accessed July 8, 2009.)
- What have we learnt from Vioxx?.BMJ. 2007; 334: 120-123
- On selective learning [letter].BMJ. 2007; ([published online ahead of print]. Accessed April 18, 2009.): 24
- Guidance for the public, FDA Advisory Committee members, and FDA staff on procedures for determining conflict of interest and eligibility for participation in FDA Advisory Committees.http://www.fda.gov/oc/advisory/guidancepolicyregs/acwaivercriteriafinalguidance080408.pdf(Accessed July 8, 2009.)Date: August 2008
Wright M. Controversy surrounds witness in Vioxx trial. The Facts.com Web site. July 31, 2005. http://thefacts.com/story.lasso?ewcd=c2feba40a6deb92e. Accessed July 8, 2009.
- Declaration of David Egilman. MD, MPH. Case 1:07-cv-00504-JBW-RLM Document 79-2 Filed 09/07/2007.(Accessed July 8, 2009.)
- Judge rules drug documents must be returned to Eli Lilly.The New York Times. February 14, 2007; (Accessed July 8, 2009.)
- Doctor who leaked documents will pay $100,000 to Lilly.The New York Times. September 8, 2007; (Accessed July 8, 2009)
- He's taking on Vioxx maker on its home turf: lawyer's winning Texas style to be tested in New Jersey.The Boston Globe. February 26, 2006; (Accessed July 8, 2009.)
- Medical journals are an extension of the marketing arm of pharmaceutical companies.PLoS Med. 2005; 2 (Epub 2005 May 17.): e138
- The ADVANTAGE seeding trial: a review of internal documents.Ann Intern Med. 2008; 149: 251-258
- Shattuck lecture: evaluating the health risks of breast implants: the inter-play of medical science, the law, and public opinion.N Engl J Med. 1996; 334: 1513-1518
- Simvastatin with or without ezetimibe in familial hypercholesterolemia [published correction appears in N Engl J Med. 2008;358(18):1977].N Engl J Med. 2008; 358 (Epub 2008 Mar 30.): 1431-1443
- Intensive lipid intervention in the post-ENHANCE era [editorial].Mayo Clin Proc. 2008; 83: 867-869
- Low-density lipoprotein cholesterol reduction and prevention of cardiovascular disease [editorial].Mayo Clin Proc. 2009; 84: 307-309
The speech that maimed Schering and Merck. Forbes.com Web site, April 3, 2008. http://www.forbes.com/2008/04/03/vytorin-merck-schering-biz-healthcare-cx_mh_0402schering.html. Accessed July 8, 2009.
- Communicating medical news-pitfalls of health care journalism.N Engl J Med. 2009; 360: 1-3
- Merck wrote drug studies for doctors.The New York Times. April 16, 2008; (Accessed July 8, 2009.)
- Merck guidelines for publication of clinical trials and related works.(Accessed July 8, 2009.)
- The “file drawer” phenomenon: suppressing clinical evidence [editorial].CMAJ. 2004; 170 (439.): 437
- Principles on conduct of clinical trials and communication of clinical trial results. PhRMA Web site.(Accessed July 8, 2009.)
- An authors' and editors' problem: authorship [editorial].Europ Sci Editing. 2003; 29 (Accessed July 8, 2009.): 4
- Authorship: why not just toss a coin?.Am J Physiol Cell Physiol. 2008; 295: C567-C575
- A descriptive analysis of authorship within medical journals, 1995-2005.South Med J. 2007; 100: 371-375
- Disclosure of researcher contributions: a study of original research articles in The Lancet.Ann Intern Med. 1999; 130: 661-670
- The vexed question of authorship: views of researchers in a British medical facility.BMJ. 1997; 314: 1009-1012
- Authorship criteria and disclosure of contributions: comparison of 3 general medical journals with different author contribution forms.JAMA. 2004; 292: 86-88
- Prevalence of honorary and ghost authorship in Cochrane reviews.JAMA. 2002; 287: 2769-2771
- Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry?.PLoS Med. 2007; 4: e286
- Information for Authors. Neurology Web site.(Accessed July 13, 2009.)
- Medical writers and peer-reviewed journals: understanding the rules and responsibilities. Keyword Pharma Web site. June 2007:3–13.(Accessed July 13, 2009.)
- Industry funding of medical education: report of an AAMC Task force, Page 22. Published June 2008.(Accessed July 13, 2009.)
- Does declaration of competing interests affect readers' perceptions? A randomised trial.BMJ. 2002; 325: 1391-1392
- The Lancet and advertorials [published correction appears in Lancet. 2009;373(9678):1848] [letter].Lancet. 2009; 373: 1004
- Response from academic authors [letter reply].Lancet. 2009; 373: 1004-1005
- Writing for the Lancet. Lancet web site.(Accessed July 13, 2009.)
- Financial associations of authors [editorial].N Engl J Med. 2002; 346: 1901-1902
- Publishing commentary by authors with potential conflicts of interest: when, why and how [editorial].Ann Intern Med. 2004; 141 (The editors.): 73-74
- Conflict of interest: the new McCarthyism in science.JAMA. 1993; 269: 2782-2784
- The pharmaceutical industry: to whom is it accountable? [editorial].N Engl J Med. 2000; 342: 1902-1904
- Citing ethics, some researchers are rejecting industry pay.The New York Times. April 15, 2008; (Accessed July 13, 2009.)
- Courts reject two major Vioxx verdicts.The New York Times. May 30, 2008; (? Accessed July 13, 2009.)
- PhRMA clinical study results database proposal. Pharmaceutical Research and Manufacturers of America Web site, 2004.(Accessed July 13, 2009.)
- Joint position on the disclosure of clinical trial information via clinical trial registries and databases.(Accessed July 13, 2009.)
- Revised clinical trial principles reinforce PhRMA's commitment to transparency and strengthen authorship standards [press release]. Washington, DC.http://www.phrma.org/news_room/press_releases/revised_clinical_trial_principles_reinforce_phrma%92s_commitment_to_transparency/(Accessed July 13, 2009.)Date: April 20, 2009
- Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes [published correction appears in N Engl J Med. 2007;357(1):100].N Engl J Med. 2007; 356 (Epub 2007 May 21.): 2457-2471
- Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death.Ann Intern Med. 2007; 147 (Epub 2007 Aug 6.): 578-581
- Rosiglitazone: a thunderstorm from scarce and fragile data [editorial].Ann Intern Med. 2007; 147: 585-587
- Doing more good than harm: need for a cease fire.Am J Med. 2009; 122: 315-316
- Is sunlight always the best disinfectant? Are financial conflicts of interest in research inherently unhealthy? Science Progress. Published Feburary 18, 2009.(Accessed July 13, 2009.)
- Regulating academic-industrial research relationships—solving problems or stifling progress?.N Engl J Med. 2005; 353: 1060-1065
- Submitted statement of the Center for Science in the Public Interest. Institute of Medicine Board on Health Science Policy - Committee on Conflicts of Interest in Medical Research, Education and Practice.http://www.iom.edu/CMS/3740/47464/49428/52483.aspx(Accessed July 13, 2009.)Date: March 13, 2008
- Research misconduct 1974-1990: an imperfect history.in: Lock S Wells F Farthing M Fraud and Misconduct in Biomedical Research. 3rd ed. BMJ Books, London, England2001: 51-63
- Research misconduct, retraction, and cleansing the medical literature: lessons from the Poehlman case.Ann Intern Med. 2006; 144 (Epub 2006 Mar 6.): 609-613
- Financial conflict of interest disclosure and voting patterns at Food and Drug Administration drug advisory committee meetings.JAMA. 2006; 295: 1921-1928
Article Info
Footnotes
Dr Hirsch was an employee at Merck & Co from 1988-2006 and managed the Medical Communications Department for clinical research publications from late 2001 to mid-2006. He currently is employed at a medical device and technology company that has no financial interest in any matters related to rofecoxib or the resulting tort litigation involving Merck & Co. Dr Hirsch owns mutual funds with stock from a variety of pharmaceutical and device companies, including Merck, and some shares of Merck and other medical product companies. He is a founding member and prior president of ISMPP (International Society for Medical Publication Professionals), a nonprofit 501(c)6 organization (www.ismpp.org). The views in this article are those of Dr Hirsch alone. The article was not reviewed or edited by individuals at any of the aforementioned organizations.
This work was presented in part at the Annual Meeting of the Council of Science Editors, May 3, 2009, Pittsburgh, PA, and at the Charter Meeting of the Association of Clinical Researchers and Educators (ACRE), July 23, 2009, Boston, MA.
This article is freely available on publication, because the author has chosen the immediate access option.
Identification
Copyright
ScienceDirect
Access this article on ScienceDirectLinked Article
- Bidirectional Conflicts of Interest Involving Industry and Medical Journals: Who Will Champion Integrity?Mayo Clinic ProceedingsVol. 84Issue 9